Interests
Biomedical Engineering
Therapeutic design
Drug discovery, design, & delivery
Oncology & infectious disease immunotherapy
Dementia therapeutics & vaccine design
iNeuron Cell Therapy
Ocular Biology
Anti-bacterials
Phage-based therapeutic platforms
Phage-based biomanufacturing
Vaccines
Gene editting
Targeted gene therapy
Nanomaterials
Biotechnology & biosensors
Roderick Slavcev
Principle Investigator
Roderick Slavcev is an associate professor with the University of Waterloo’s School of Pharmacy. Dr. Slavcev’s research specializes in bacteriophage-based biotechnology and exploits phage genetic systems and phage themselves in the generation of novel therapeutic platforms. With a particular focus on coliphages, his lab’s research designs and constructs vectors for novel vaccines, gene delivery systems, and immunotherapeutics. In addition, his team identifies and applies novel phage genomic anti-bacterial genes with potential phage therapy applications. Research in the Theraphage lab is heavily multidisciplinary, integrating genetics, molecular biology, microbiology, gene therapy, virology, therapeutic design, and synthetic in vivo biology.
Roderick comes to the University of Waterloo with a MBA specialized in biotechnology management and commercialization. As the Professor of Business and Entrepreneurship, Roderick currently directs and delivers the School of Pharmacy's award-winning business curriculum initiative. He was also instrumental in the designing and development of the first Medical Microbiology Laboratory to be offered by a Canadian Pharmacy curriculum and leads the development of a Continuing Education initiative to bring Strategic Management and Leadership to practicing pharmacists.
Dr. Slavcev is also the Chief Technology Officer of Mediphage Bioceuticals in Toronto, as well as a Principle Investigator at the Centre for Eye and Vision Research (CEVR) in Hong Kong.
Education
B.Sc. Honours in Human Biology, University of Toronto (1995)
Ph.D. in Microbial Genetics, University of Saskatchewan (2002)
Research Associate Fellowship Medical Genetics, University of Toronto (2005)
M.B.A. in Biotechnology Management and Commercialization, Edwards School of Business, University of Saskatchewan (2006)
Contact
roderick.slavcev@theraphage.bio
Selected Publications
Talebnia, F., Pushparajah, D., Chandrasekaran, S., Hersch, S. J., Nafissi, N., & Slavcev, R. (2023). Application of an electro elution system for direct purification of linear covalently closed DNA fragments. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1218, 123622. doi: 10.1016/j.jchromb.2023.123622.
Wong, Shirley & Jimenez, Salma & Slavcev, Roderick. (2023). Construction and characterization of a novel miniaturized filamentous phagemid for targeted mammalian gene transfer. Microbial Cell Factories. 22. 10.1186/s12934-023-02135-w.
St. Jean, Jesse & Slavcev, Roderick & Nekkar Rao, Praveen (2023). The effects of amyloid beta aggregation on neuronal transcription. IBRO Neuroscience Reports. 14: 375–379.
Huh, Haein & Chen, Ding-Wen & Foldvari, Marianna & Slavcev, Roderick & Blay, Jonathan. (2022). EGFR-targeted bacteriophage lambda penetrates model stromal and colorectal carcinoma tissues, is taken up into carcinoma cells, and interferes with 3-dimensional tumor formation. Frontiers in Immunology. 13. 10.3389/fimmu.2022.957233.
Wong, Shirley & Alattas, Hibah & Slavcev, Roderick. (2021). A snapshot of the λ T4rII exclusion (Rex) phenotype in Escherichia coli. Current Genetics. 67. 10.1007/s00294-021-01183-2.
Pushparajah, Deborah & Jimenez, Salma & Wong, Shirley & Alattas, Hibah & Nafissi, Nafiseh & Slavcev, Roderick. (2021). Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Advanced Drug Delivery Reviews. 170. 10.1016/j.addr.2021.01.003.
Alattas, Hibah & Wong, Shirley & Slavcev, Roderick. (2020). Identification of Escherichia coli Host Genes That Influence the Bacteriophage Lambda (λ) T4rII Exclusion (Rex) Phenotype. Genetics. 216. 10.1534/genetics.120.303643.
Huh, Haein & Wong, Shirley & St. Jean, Jesse & Slavcev, Roderick. (2019). Bacteriophage Interactions with Mammalian Tissue: Therapeutic Applications. Advanced Drug Delivery Reviews. 145. 10.1016/j.addr.2019.01.003.
Razazan, Atefeh & Nicastro, Jessica & Slavcev, Roderick & Barati, Nastaran & Arab, Atefeh & Mosaffa, Fatemeh & Jaafari, mahmoud reza & Behravan, Javad. (2019). Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice. Scientific Reports. 9. 2221. 10.1038/s41598-018-38371-z.
Arab A, Behravan N, Razazn A, Barati N, Mosaffa F, Nicastro J, Slavcev R, Behravan J. The viral approach to breast cancer immunotherapy. J Cell Physiol. 2019 Feb;234(2):1257-1267. doi: 10.1002/jcp.27150. Epub 2018 Aug 26. PMID: 30146692.
Arab, Atefeh & Yazdian robati, Rezvan & Nicastro, Jessica & Slavcev, Roderick & Behravan, Javad. (2018). Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer. Current Pharmaceutical Design. 24. 10.2174/1381612824666180327152117.
Barati, Nastaran & Razazan, Atefeh & Nicastro, Jessica & Slavcev, Roderick & Arab, Atefeh & Mosaffa, Fatemeh & Nikpoor, Amin & Badiee, Ali & Jaafari, mahmoud reza & Behravan, Javad. (2018). Immunogenicity and antitumor activity of the superlytic λF7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer Letters. 424. 10.1016/j.canlet.2018.03.030.
Arab, Atefeh & Nicastro, Jessica & Slavcev, Roderick & Razazan, Atefeh & Barati, Nastaran & Nikpoor, Amin & Momtazi, Amir Abbas & Mosaffa, Fatemeh & Badiee, Ali & Jaafari, mahmoud reza & Behravan, Javad. (2018). Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunologic Research. 66. 10.1007/s12026-017-8969-0.
Patents
Slavcev, R. and N. Nafissi. 2023. Vectors for Producing Virus-Like Particles and Uses Thereof.
Slavcev, R. and N. Nafissi. 2022. DNA Vector Production System.
Slavcev, R. and N. Nafissi. 2022. DNA Vector Production System.
Slavcev, R., Huh H., and J. Blay. 2021. EGFR Binding Moiety-Presenting Bacteriophages for Tumor Treatment.
Slavcev, R. and Behravan, J. 2020. Fusion Protein Comprising Bacteriophage λ GPD Fused to a GP2 Antigen Derived from HER-2/NEU.
Slavcev and J. Behravan. 2018. Peptide Displaying Bacteriophage Nanoparticles and Related Compositions and Methods. WO/2019/102265
Slavcev, R. and N. Nafissi. 2016. DNA Vector System US 8926184 B2
Slavcev, R. and J. Nicastro. 2015. A Fine-tuned Lytic Phage Display System. USPTO serial #: 61/815467
Slavcev, R. and N. Nafissi. 2014. In vivo linear covalently closed DNA vector production system. USPTO serial #: 61/729,384
Slavcev, R. and N. Nafissi. 2016. (CIP) DNA Vector System. US 20160333361 A1
Books
Bacteriophage Applications—Historical Perspective and Future Potential.
Jessica Nicastro, Shirley Wong, Zahra Khazaei, Peggy Lam, Jonathan Blay, Roderick A. Slavcev.
Cham: Springer Nature Publishing (2017)Pharmacy Management in Canada. Vol. 1.
Roderick A. Slavcev, Alan Low, Jason Perepelkin, Rita Winn, Kevin Hall, Mike Jaczko, Dayle Acorn
Toronto: Brush Publishing (2015)Tackling the classical genetic mystery of the bacteriophage λ Rex phenotype.
Slavcev, Roderick A.
Köln: Lambert Academic Publishing (2010)
Awards
ASGCT Research Award
WIN Research Award
JNJ Innovation Labs Technology Award
Illumina Next Generation Sequencing Award
Association of Faculties of Pharmacy of Canada (AFPC) & Janssen Innovation in Education Award
Affiliations & Associations
Cross-appointment to Department of Chemistry, Department of Biology, & Department of Chemical Engineering at the University of Waterloo
Member of Center of Bioengineering & Biotechnology, Waterloo Institute of Nanotechnology, Waterloo Centre for Microbial Research, & Bioworks Research Group
Chartered Biologist, Royal Society of Biology (MRSB, C. Biol designation)
Member, American Society for Gene & Cell Therapy, 2012-present
Member, American Society for Microbiology (ASM)
Member, Canadian Society for Microbiology